

April 14, 2026



# Perimeter Medical Imaging AI to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference



TORONTO and DALLAS, April 14, 2026 /CNW/ - [Perimeter Medical Imaging AI, Inc.](#) (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that management will present an update on the Company's business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 21, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will also be broadcast live and archived on the Company's website under "[News/Events](#)" in the [Investors](#) section.

## **About Perimeter Medical Imaging AI, Inc.**

Based in Toronto, Canada and Dallas, Texas, [Perimeter Medical Imaging AI](#) (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire™, recently approved by the U.S. Food and Drug Administration (FDA), is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

*Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.*

*The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating,*

*patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information.*

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

## **Contacts**

Stephen Kilmer  
Investor Relations  
Direct: 647-872-4849  
Email: [skilmer@perimetermed.com](mailto:skilmer@perimetermed.com)

Susan Thomas  
Media Relations  
Direct: 619-540-9195  
Email: [susan@endpointcommunications.net](mailto:susan@endpointcommunications.net)

Adrian Mendes  
Chief Executive Officer  
Toll-free: 888-988-7465 (PINK)  
Email: [investors@perimetermed.com](mailto:investors@perimetermed.com)

📄 View original content to download multimedia <https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-to-participate-in-the-2026-bloom-burton--co-healthcare-investor-conference-302741280.html>

SOURCE Perimeter Medical Imaging AI Inc.